Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Denosumab Market Value Analysis: What Growth Lies Ahead Over The Forecast Period?
The denosumab market has experienced significant growth in recent years. It is anticipated to expand from $3.67 billion in 2025 to $4.06 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.7%. The historical increase can be ascribed to the high prevalence of osteoporosis and bone-related disorders, an expanding geriatric population, swift approvals for denosumab therapies, growing capacities in hospitals and specialty clinics, and increased patient awareness regarding fracture risk.
The denosumab market is projected for significant expansion, reaching $6.06 billion by 2030, driven by a compound annual growth rate (CAGR) of 10.5%. This anticipated expansion throughout the forecast period stems from factors such as progress in precision medicine and biologics, broader availability of homecare and ambulatory services, heightened investment in bone health studies, the launch of advanced denosumab formulations, and increasing demand across developing markets. Key developments expected during this period encompass a greater acceptance of monoclonal antibodies, the extension of osteoporosis screening initiatives, tailored treatment strategies for bone metastases, an increase in home-administered injection therapies, and a growing understanding of bone health needs among the elderly population.
Get A Free Sample Report With In-Depth Market Insights:
Denosumab Market Demand Drivers: What’s Powering Industry Growth?
The rising occurrence of osteoporosis is projected to fuel the expansion of the denosumab market in the coming years. Osteoporosis is a condition characterized by weakened bones, reduced bone density, and an elevated risk of fractures. Denosumab serves as a treatment for osteoporosis by inhibiting bone resorption through its action on the RANK ligand. For instance, data from the Canadian Longitudinal Study on Aging, as reported by the National Center for Biotechnology Information in September 2023, indicated that among community-dwelling older adult females, the prevalence of physician-diagnosed osteoporosis was 12.7% and DXA-confirmed osteoporosis was 5.9%. Furthermore, a cross-sectional study by Buttros and colleagues identified a 24.6% prevalence of osteoporosis, diagnosed through bone mineral density (BMD) measurements, in postmenopausal women aged 40 to 75. Consequently, the increasing prevalence of osteoporosis is a key factor driving the growth of the denosumab market.
Denosumab Market Driver: Expansion Of The Healthcare Industry Fueling The Growth Of The Market Due To Rising Demand For Advanced Therapies For Bone-Related Conditions
Denosumab Market Segment Breakdown: Which Categories Lead On Revenue?
The denosumab market covered in this report is segmented –
1) By Drug Classification: Prolia, Xgeva
2) By Type: 60 mg, 120 mg
3) By End-Users: Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers
Subsegments:
1) By Prolia: Prolia 60 Mg Injection, Prolia 1-Year Dosing Schedule, Prolia Osteoporosis Treatment
2) By Xgeva: Xgeva 120 Mg Injection, Xgeva Monthly Dosing Schedule, Xgeva Bone Metastases Management
Denosumab Market Innovation Trends: What Developments Are Reshaping The Industry?
Major companies operating in the denosumab market are prioritizing the expansion of their global clinical investigations and expediting regulatory clearances to enhance their competitive standing and broaden access to treatment. Clinical trials are human-based studies engineered to evaluate the effectiveness and safety of new drugs or therapies. For instance, in May 2023, Boan Biotech, a China-based biopharma company, launched an international multi center Phase 3 clinical trial for its denosumab biosimilars BA6101 (Boyoubei) and BA1102, enrolling the first patient in Europe, the U.S., and Japan. These endeavors succeed its 2022 NMPA approval for Boyoubei in postmenopausal women at high fracture risk. By progressing global clinical development and achieving regulatory momentum, companies strengthen their competitiveness in the denosumab market.
Denosumab Market Leading Players And Competitive Positioning
Major companies operating in the denosumab market are Amgen Inc., Fresenius SE & Co KGaA, Amneal Pharmaceuticals Inc., Dr Reddy’s Laboratories Ltd, Biocon Ltd, Sandoz Group AG, Samsung Bioepis Co Ltd, Celltrion Inc, Organon & Co, Shanghai Henlius Biotech Inc, Teva Pharmaceutical Industries Ltd, Accord Healthcare Ltd, CuraTeQ Biologics Pvt Ltd, AryoGen Pharmed Co, BioXpress Therapeutics AG, Henlius Biotech Co Ltd, JHL Biotech Inc, Oncobiologics Inc, Teva International GmbH (Teva biosimilars unit), Hikma Pharmaceuticals PLC, Gedeon Richter Plc, Accord BioPharma Inc
View The Full Denosumab Market Report:
Denosumab Market Top Region: Where Does Most Revenue Come From?
North America was the largest region in the denosumab market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the denosumab market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
